DLCIG
CRSP icon

D.L. Carlson Investment Group’s CRISPR Therapeutics CRSP Stock Holding History

D.L. Carlson Investment Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-37,012
Closed -$4.51M – 149
2021
Q1 		$4.51M Sell
37,012
-2,428
-6% -$367K 0.82% 52
2020
Q4 		$6.04M Sell
39,440
-8,663
-18% -$1.02M 1.1% 31
2020
Q3 		$4.02M Buy
48,103
+21,458
+81% +$1.9M 0.85% 47
2020
Q2 		$1.96M Buy
+26,645
New +$1.56M 0.58% 60

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

D.L. Carlson Investment Group's CRSP Position: Q2 2021 in Review

D.L. Carlson Investment Group sold out of CRISPR Therapeutics (CRSP) in Q2 2021, closing a stake of 37,012 shares — an estimated $4.51M sold.

D.L. Carlson Investment Group first reported a position in CRSP in Q2 2020 and held it in 4 quarters. The position peaked at $6.04M in Q4 2020. 498 funds tracked by Wall St. Rank hold CRSP as of Q2 2021.

  • D.L. Carlson Investment Group reported no remaining CRISPR Therapeutics position as of Q2 2021 after selling out during the quarter.
  • D.L. Carlson Investment Group sold 37,012 CRISPR Therapeutics shares in Q2 2021, an estimated $4.51M.
  • D.L. Carlson Investment Group first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 4 quarters.
  • D.L. Carlson Investment Group's CRISPR Therapeutics position peaked at $6.04M in Q4 2020.
  • 498 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2021.

Based on D.L. Carlson Investment Group's 13F filing for Q2 2021, filed 12 Aug 2021.